What should be monitored in patients receiving aminoglycosides?

Monitoring kidney function in patients receiving aminoglycosides is critically important due to the potential nephrotoxicity associated with these medications. Aminoglycosides, such as gentamicin and tobramycin, are primarily eliminated by the kidneys, and their use can lead to increased serum creatinine levels and decreased glomerular filtration rate (GFR). Therefore, assessing renal function through serum creatinine measurements and urine output helps ensure that the drug is being safely metabolized and excreted.

In addition, thorough monitoring allows healthcare providers to adjust dosing appropriately and take early action if signs of nephrotoxicity present themselves. This proactive approach can significantly reduce the risk of permanent kidney damage associated with aminoglycoside therapy. While liver function, electrolyte levels, and blood glucose levels are important in other contexts, they do not specifically relate to the primary toxic effects seen with aminoglycoside use.